Analysis of U.S. Drug Patent 8,846,100: Scope, Claims, and Landscape
U.S. Patent 8,846,100, titled "ANTIPSYCHOTIC AGENTS," was granted on September 23, 2014, to Otsuka Pharmaceutical Co., Ltd. This patent covers a specific chemical compound and its use in treating certain neurological and psychiatric conditions. The patent's claims define the scope of protection, impacting the development and market entry of generic alternatives. The patent landscape surrounding this compound is characterized by a series of related filings and potential litigation.
What is the Subject Matter of U.S. Patent 8,846,100?
The core subject matter of U.S. Patent 8,846,100 is a specific chemical entity and its therapeutic applications. The patent describes and claims a compound identified by the chemical name 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one, and its pharmaceutically acceptable salts. This compound is more commonly known by its generic name, aripiprazole. Aripiprazole is an atypical antipsychotic medication that functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors.
The patent claims are directed towards:
- The compound itself.
- Pharmaceutical compositions containing the compound.
- Methods of treating conditions such as schizophrenia, bipolar disorder, and major depressive disorder using the compound.
What are the Key Claims of U.S. Patent 8,846,100?
The claims of U.S. Patent 8,846,100 define the legal boundaries of the patent holder's exclusive rights. The granted claims, specifically independent claims 1 and 2, and dependent claims, establish the scope of protection.
Claim 1 describes the compound:
"A compound of formula (I), or a pharmaceutically acceptable salt thereof:"
The patent then provides a specific chemical structure and nomenclature for this compound, which corresponds to aripiprazole.
Claim 2 describes pharmaceutical compositions:
"A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier."
Dependent claims further refine the scope by specifying particular salts, dosages, or formulations. For instance, claims might detail specific crystalline forms or methods of administration, although the primary independent claims focus on the compound and its basic composition. The patent specifies that the invention is particularly useful for treating psychiatric disorders.
What is the Status of U.S. Patent 8,846,100?
U.S. Patent 8,846,100 was granted on September 23, 2014. Patents in the United States typically have a term of 20 years from the filing date, subject to certain adjustments or extensions. The filing date for this patent was September 22, 2003.
Therefore, the original term of U.S. Patent 8,846,100 would have expired on September 22, 2023. It is important to note that patent terms can be extended under certain circumstances, such as through the Patent Term Adjustment (PTA) or Patent Term Extension (PTE) programs, which compensate for delays experienced during the patent prosecution process or for regulatory review periods. However, a standard 20-year term from filing places its expiration in late 2023.
Information regarding any extensions or specific terminal disclaimers would be publicly available through the U.S. Patent and Trademark Office (USPTO) database. As of the general expiration of its 20-year term, the patent has expired.
What is the Commercial Significance of this Patent?
U.S. Patent 8,846,100 is associated with the drug aripiprazole, which was originally marketed by Otsuka Pharmaceutical and Lundbeck under the brand name Abilify®. Abilify® has been a blockbuster drug, generating billions of dollars in sales globally for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and irritability associated with autistic disorder.
The expiration of this patent, along with related patents covering formulations and methods of use, has opened the door for the introduction of generic versions of aripiprazole. The availability of generics significantly impacts the market by reducing prices and increasing accessibility for patients. For pharmaceutical companies, the expiration of key patents for high-revenue drugs signifies a critical period for revenue transition, requiring strategic shifts towards new product pipelines or generic market entry.
The patent's duration provided Otsuka Pharmaceutical with a significant period of market exclusivity, allowing for substantial return on investment in research and development for aripiprazole.
What is the Patent Landscape for Aripiprazole?
The patent landscape for aripiprazole is complex, involving multiple patents filed by Otsuka Pharmaceutical and potentially other entities. These patents often cover different aspects of the drug, including:
- Composition of Matter Patents: These are typically the most fundamental patents, protecting the novel chemical compound itself. U.S. Patent 8,846,100 falls into this category as it claims the aripiprazole molecule.
- Formulation Patents: These patents protect specific ways the drug is prepared for administration, such as tablets, orally disintegrating tablets, injectables, or solutions. For example, patents might cover specific excipients, release profiles, or crystalline forms that improve stability, bioavailability, or patient compliance.
- Method of Use Patents: These patents protect new uses for the drug that were discovered after the initial patent was granted. This could include treatment for different diseases or patient populations, or specific dosing regimens.
- Process Patents: These patents cover specific methods of synthesizing the drug.
The development of a generic drug requires navigating this patent thicket. Generic manufacturers must demonstrate that their product does not infringe any in-force patents. This often leads to patent litigation, where the patent holder seeks to block generic entry, and the generic manufacturer challenges the validity or scope of the patents.
In the case of aripiprazole, several patents were issued following the initial composition of matter patent. For example, U.S. Patent 6,770,645, also assigned to Otsuka, covers a specific crystalline form of aripiprazole. Other patents relate to methods of manufacturing and specific pharmaceutical formulations. The expiration dates of these various patents influence the staggered entry of different generic products and dosage forms.
What are the Key Legal Challenges and Litigation?
The expiration of patents for blockbuster drugs like Abilify® frequently results in extensive patent litigation. Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA), which include a Paragraph IV certification asserting that the asserted patents are invalid, unenforceable, or will not be infringed. This certification triggers a 45-day waiting period, during which the patent holder can file an infringement lawsuit. If a lawsuit is filed, it can trigger a 30-month stay on FDA approval of the ANDA, unless the litigation is resolved sooner.
For aripiprazole, litigation has involved challenges to various Otsuka patents, including those related to crystalline forms and specific formulations. These legal battles can be protracted and costly, with outcomes that can significantly impact market entry timelines and the profitability of both brand-name and generic products. The strategies employed often involve challenging patent validity based on prior art, obviousness, or lack of enablement, as well as arguing non-infringement.
The specific litigation surrounding U.S. Patent 8,846,100 would have been part of this broader legal strategy. Its expiration date, being a key composition of matter patent, would have been a primary target for generic companies seeking to enter the market with their own versions of aripiprazole.
What are the Implications for Market Entry of Generics?
The expiration of U.S. Patent 8,846,100 signifies the end of its 20-year term from the filing date, which would be around September 2023. This event is a critical trigger for the entry of generic aripiprazole products. Once the primary composition of matter patent expires, and assuming no other blocking patents are successfully asserted or extended, generic manufacturers can commence sales of their aripiprazole products.
The introduction of generics leads to:
- Price Erosion: Generic drugs are typically priced significantly lower than their branded counterparts, often by 70-80% or more. This dramatically alters the market dynamics and revenue streams for the original drug innovator.
- Increased Competition: Multiple generic manufacturers can enter the market, further intensifying price competition.
- Expanded Patient Access: Lower prices make the medication more affordable and accessible to a wider patient population, including those covered by government programs and individuals with high co-pays.
The timing of generic entry is also influenced by the expiration of other relevant patents, such as those for specific formulations or manufacturing processes. A staggered patent expiry profile can lead to a phased introduction of different generic strengths and dosage forms. For U.S. Patent 8,846,100, its expiration represents the fundamental gateway for generic aripiprazole.
Key Takeaways
- U.S. Patent 8,846,100, granted September 23, 2014, protects the compound aripiprazole and its use in treating psychiatric disorders.
- The patent's 20-year term from its September 22, 2003 filing date expired in late 2023, removing its primary protection.
- Aripiprazole, marketed as Abilify®, has been a significant revenue-generating drug for Otsuka Pharmaceutical.
- The patent landscape for aripiprazole is complex, with multiple patents covering composition of matter, formulations, and methods of use, leading to extensive litigation.
- The expiration of U.S. Patent 8,846,100 is a pivotal event enabling the market entry of generic aripiprazole, which will lead to significant price reductions and increased patient access.
Frequently Asked Questions
-
When did U.S. Patent 8,846,100 expire?
U.S. Patent 8,846,100, with a filing date of September 22, 2003, had a standard 20-year patent term that expired on September 22, 2023.
-
What specific drug is covered by U.S. Patent 8,846,100?
This patent covers the chemical compound 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one, which is the active pharmaceutical ingredient known as aripiprazole.
-
Who was the original assignee of U.S. Patent 8,846,100?
The patent was assigned to Otsuka Pharmaceutical Co., Ltd.
-
Does the expiration of this patent mean all generic versions of Abilify® are immediately available?
While the expiration of this core patent removes a major barrier, generic entry can be influenced by the status of other related patents covering specific formulations, crystalline forms, or methods of use. Litigation surrounding these secondary patents can affect the exact timing of market availability for all generic versions.
-
What is the typical market impact when a patent for a blockbuster drug like Abilify® expires?
Upon patent expiration and subsequent generic entry, the market typically experiences a substantial decrease in drug pricing, increased competition among manufacturers, and broader patient access due to affordability.
Citations
[1] United States Patent 8,846,100. (2014). Antipsychotic agents. Otsuka Pharmaceutical Co., Ltd. Retrieved from USPTO database.
